import { jsx as _jsx, jsxs as _jsxs } from "react/jsx-runtime";
import CitationCard from "@/app/components/citation-card/citation-card";
import Figure from "@/app/components/figure/figure";
import Hypothesis from "@/app/components/hypothesis/hypothesis";
import { MyNode } from "@/models/node";
import { MMSEReview, NIAAA } from "@/public/citations";
const Classifications = new MyNode("Classifications", [], (_jsxs("div", { children: [_jsx(CitationCard, { citations: [NIAAA], children: "individuals without overt symptoms, called \u201Cpreclinical AD\u201D [4]." }), _jsx(CitationCard, { citations: [NIAAA], children: "Biomarkers of AD: CSF biomarkers are valid proxies for neuropathologic changes of AD. Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Ab deposits (in brain parenchyma/vessel walls) [17\u201324].Itis also now widely accepted that CSF Ab42 (or the Ab42/ Ab40 ratio) is a valid indicator of the abnormal pathologic state associated with cerebral Ab [25]. An additional development has been the introduction of PET ligands for pathologic tau [26\u201328]. magnetic resonance imaging (MRI), fluorodeoxyglucose (FDG) PET, and CSF total tau (T-tau)\u2014are not specific for AD but rather are nonspecific indicators of damage that may derive from a variety of etiologies, for example, cerebrovascular injury [29]." }), _jsxs(CitationCard, { citations: [NIAAA], children: [_jsx(Figure, { src: "images/classifcation/classification.png", alt: "Classification problem", caption: "Interaction of ATN features", n: 1 }), _jsx(Figure, { src: "images/classifcation/atn_niaaa.png", alt: "ATN X NIA-AA", caption: "Biomarkers interactions with NIA-AA", n: 2 })] }), _jsx(CitationCard, { citations: [NIAAA], children: "Comparision NIA-AA with IWG: The International Working Group (IWG) also incorporates biomarkers in AD diagnosis but requires cognitive symptoms alongside biomarkers for diagnosis (except for genetic AD). Unlike NIA-AA\u2019s purely biological model, IWG initially required clinical symptoms to define AD. However, IWG\u2019s 2016 update included asymptomatic individuals with both abnormal A\u03B2 and tau biomarkers in the AD category, aligning more closely with NIA-AA\u2019s biologic definition." }), _jsx(CitationCard, { citations: [NIAAA], children: "Alzheimer\u2019s clinical syndrome rather than probable AD when describing syndromes without biomarker evidence" }), _jsx(Hypothesis, { children: _jsx(Figure, { src: "images/causality/causal_hypothesis.png", alt: "Hypothesis", caption: "The possible causalities of the biomarkers", n: 1 }) }), _jsx(CitationCard, { citations: [MMSEReview], children: "he prevalence of cognitive impairment without dementia as 22% in people aged 71 years or older (Plassman 2008).10% to 15% of individuals with MCI may progress to dementia," })] })));
export default Classifications;
